Obesity Pharmacotherapy

The strongest refinements in the update concern weight loss and liver disease. The update revises an existing treatment algorithm rather than introducing obesity pharmacotherapy as a new concept. The pharmacological treatment framework is intended to guide structured decisions based on patient characteristics, goals, complications, and comparative evidence. During weight maintenance, reduced energy expenditure and increased energy efficiency lower caloric needs and make regain more likely. Weight regain can reverse cardiometabolic improvements and worsen physical and psychological burden. The trial argues against the misconception that obesity medications can simply be stopped after weight loss. The 2026 EASO update refines a framework for pharmacological treatment of obesity and obesity-related complications. Sustained therapy is considered important for preserving reduced body weight and cardiometabolic improvements. The findings support continued pharmacotherapy for people who have lost weight with obesity medications. Weight-loss medications are framed as part of a broader clinical conversation rather than a default recommendation. Treatment choices for weight-loss medications…